Table 3.
Summary of Best Overall Response for Subjects With a Baseline Diagnosis of CLL/SLL
| AVL‐292 Dosing Cohorts | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | 125 mg QD n (%) | 250 mg QD n (%) | 400 mg QD n (%) | 625 mg QD n (%) | 750 mg QD n (%) | 1000 mg QD n (%) | 375 mg BID n (%) | 500 mg BID n (%) | Total n (%) |
| Baseline diagnosis: CLL/SLL | |||||||||
| n | 3 | 1 | 4 | 1 | 29 | 7 | 6 | 31 | 82 |
| Best overall response | |||||||||
| Complete response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial response | 1 (33.3) | 0 | 1 (25.0) | 0 | 12 (41.4) | 4 (57.1) | 4 (66.7) | 19 (61.3) | 41 (50.0) |
| Stable disease | 2 (66.7) | 1 (100) | 3 (75.0) | 1 (100) | 16 (55.2) | 3 (42.9) | 2 (33.3) | 12 (38.7) | 40 (48.8) |
| Progression disease | 0 | 0 | 0 | 0 | 1 (3.4) | 0 | 0 | 0 | 1 (1.2) |
| Overall response rate | 1 (33.3) | 0 | 1 (25.0) | 0 | 12 (41.4) | 4 (57.1) | 4 (66.7) | 19 (61.3) | 41 (50.0) |
CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma.